Biogen Inc. (Nasdaq: BIIB) has announced the initiation of three pivotal Phase 3 clinical studies for its investigational drug, felzartamab, targeting rare kidney diseases. These studies, set to commence in 2025, aim to explore the potential of felzartamab, an anti-CD38 monoclonal antibody, in treating a range of immune-mediated diseases. The first readouts from these studies are expected in 2027. The announcement was made during a virtual investor seminar, where Biogen highlighted its strategic expansion into immunology and rare diseases following the acquisition of Human Immunology Biosciences in 2024. Results from these studies will be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.